Use of inhaled corticosteroids (CS) during pregnancy does not reduce fetal growth

Namazy, J.A.; Schatz, Michael; Long, D. Leann; Petitti, Diana

doi:10.1016/s0091-6749(03)80959-4

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although limited for most ICSs, several studies in pregnant women 34,35,[39][40][41][42][43][44][45][46][47] have demonstrated the safety of ICSs in terms of perinatal outcomes, including the rate of congenital malformations, prematurity, and fetal birth weight. In a recent report of 392 infants born to women treated with various ICSs (beclomethasone 51.2%, fluticasone 33.8%, triamcinolone 20.2%, budesonide 10.2%, and flunisolide 6.4%; 19.6% used more than one specific ICS), no significant relationship was seen between the dose of ICS used and mean birth weight or the incidence of small for gestational age births.…”

Section: Asthma and Rhinitis Medicationsmentioning

confidence: 99%

“…In a recent report of 392 infants born to women treated with various ICSs (beclomethasone 51.2%, fluticasone 33.8%, triamcinolone 20.2%, budesonide 10.2%, and flunisolide 6.4%; 19.6% used more than one specific ICS), no significant relationship was seen between the dose of ICS used and mean birth weight or the incidence of small for gestational age births. 44 According to the FDA, however, only studies of inhaled budesonide are sufficient (i.e., adequate and well controlled) to merit a pregnancy category B rating. Two prospective studies of Swedish Medical Birth Registry data have shown that infants exposed to inhaled budesonide during early pregnancy are not at increased risk of congenital malformations.…”

Section: Asthma and Rhinitis Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

The Management of Asthma and Rhinitis during Pregnancy

Osur¹

2005

Journal of Women's Health

View full text Add to dashboard Cite

Asthma and rhinitis frequently complicate pregnancy. The course of asthma may be adversely altered by gestation, placing the mother and fetus at risk. Therefore, pregnant patients with persistent asthma require an aggressive asthma management plan that includes environmental control measures and the use of long-term controller medications. Inhaled corticosteroids (ICSs) are the preferred long-term controller medication for persistent asthma, based on efficacy. However, safety concerns regarding corticosteroids may cause physicians or patients to seek an alternate, less effective treatment during pregnancy. The Food and Drug Administration's pregnancy category ratings are based on animal and human safety data. Because ICSs were previously rated pregnancy category C (i.e., with human studies lacking and animal studies either lacking or positive for fetal risk), other asthma controllers, such as cromolyn and nedocromil, that carry a pregnancy category B rating (i.e., showing no evidence of fetal risk in humans or animal studies negative for fetal risk) appeared to be more desirable for use during pregnancy. One ICS, budesonide, was reclassified as pregnancy category B based on human data supporting its use during pregnancy. In moderate and severe persistent asthma, add-on therapy may be considered, including long-acting beta2-adrenergic agonists, leukotriene receptor antagonists, and theophylline. Because rhinitis may adversely affect quality of life and the course of asthma, recommendations for aggressive management also apply.

show abstract